Cargando…

Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists

PURPOSE: We examined the effect of olodaterol on the risk of myocardial ischaemia, cardiac arrhythmia, and all‐cause mortality compared with use of other long‐acting beta2‐agonists (LABAs). Channelling bias was also explored. METHODS: This Danish population‐based cohort study used data linked from r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rebordosa, Cristina, Farkas, Dóra Körmendiné, Montonen, Jukka, Laugesen, Kristina, Voss, Florian, Aguado, Jaume, Bothner, Ulrich, Rothman, Kenneth J., Zint, Kristina, Mines, Daniel, Ehrenstein, Vera
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545725/ https://www.ncbi.nlm.nih.gov/pubmed/35320605 http://dx.doi.org/10.1002/pds.5432

Ejemplares similares

No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization Study
por: Rebordosa, Cristina, et al.
Publicado: (2020)

Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat(®) device for maintenance treatment of COPD: comparison with the long-acting β(2)-agonist formoterol
por: Koch, Andrea, et al.
Publicado: (2017)

Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists
por: Rebordosa, Cristina, et al.
Publicado: (2022)

Cancer Risk in Pulmonary Hypertension Patients
por: Sørensen, Henrik Toft, et al.
Publicado: (2022)

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol
por: Roskell, Neil S, et al.
Publicado: (2014)

The long-acting β(2)-adrenoceptor agonist olodaterol attenuates pulmonary inflammation
por: Wex, Eva, et al.
Publicado: (2015)

Mental Health Conditions Among Children and Adolescents With Congenital Heart Disease: A Danish Population-Based Cohort Study
por: Miles, Kimberley G., et al.
Publicado: (2023)

Cancer Diagnosis and Prognosis After Guillain–Barré Syndrome: A Population-Based Cohort Study
por: Girma, Blean, et al.
Publicado: (2022)

Use of prescription paracetamol during pregnancy and risk of asthma in children: a population-based Danish cohort study
por: Andersen, Ane Birgitte Telén, et al.
Publicado: (2012)

Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database
por: Quint, Jennifer K., et al.
Publicado: (2021)

Motor Neuron Disease and Risk of Cancer: A Population-Based Cohort Study in Denmark
por: Sørensen, Trine Toft, et al.
Publicado: (2020)

Validation of spontaneous abortion diagnoses in the Danish National Registry of Patients
por: Lohse, Sarah Rytter, et al.
Publicado: (2010)

A Post Hoc Holter ECG Analysis of Olodaterol and Formoterol in Moderate-to-Very-Severe COPD
por: Andreas, Stefan, et al.
Publicado: (2020)

Efficacy and safety of the long-acting β(2)-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease
por: Ichinose, Masakazu, et al.
Publicado: (2015)

Associations between stress disorders and cardiovascular disease events in the Danish population
por: Gradus, Jaimie L, et al.
Publicado: (2015)

Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies
por: Ferguson, Gary T., et al.
Publicado: (2020)

Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol
por: Matera, Maria Gabriella, et al.
Publicado: (2015)

Long-term safety of tiotropium/olodaterol Respimat(®) in patients with moderate-to-very severe COPD and renal impairment in the TONADO(®) studies
por: LaForce, Craig, et al.
Publicado: (2018)

Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease
por: Bai, Chunxue, et al.
Publicado: (2017)

Paradoxical Bronchoconstriction with Short-Acting Beta Agonist
por: Magee, Jared S., et al.
Publicado: (2018)

Striving for optimal bronchodilation: focus on olodaterol
por: Incorvaia, Cristoforo, et al.
Publicado: (2016)

Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019)

The Danish health care system and epidemiological research: from health care contacts to database records
por: Schmidt, Morten, et al.
Publicado: (2019)

Correction to: Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019)

Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD
por: Andreas, Stefan, et al.
Publicado: (2020)

Pneumonia diagnosis in childhood and incidence of leukaemia, lymphoma and brain cancer: a Danish nationwide cohort study
por: Søgaard, Kirstine Kobberøe, et al.
Publicado: (2017)

Risk of cardiovascular events and pulmonary hypertension following splenectomy — a Danish population-based cohort study from 1996–2012
por: Rørholt, Marianne, et al.
Publicado: (2017)

No Influence on Cardiac Arrhythmia or Heart Rate from Long-Term Treatment with Tiotropium/Olodaterol versus Monocomponents by Holter ECG Analysis in Patients with Moderate-to-Very-Severe COPD
por: Andreas, Stefan, et al.
Publicado: (2020)

The benefits of combined treatment with corticosteroids and long-acting beta agonists
por: Singh, Dave
Publicado: (2006)

Long-Acting Beta Agonists Enhance Allergic Airway Disease
por: Knight, John M., et al.
Publicado: (2015)

Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β(2)-agonist, in patients with asthma: results of a parallel-group study and a crossover study
por: O’Byrne, Paul M., et al.
Publicado: (2015)

Systematic review comparing LABA, olodaterol, and indacaterol: limitations
por: Donohue, James F
Publicado: (2014)

Efficacy of tiotropium–olodaterol fixed-dose combination in COPD
por: Derom, Eric, et al.
Publicado: (2016)

Risk of lower gastrointestinal bleeding and colorectal neoplasms following initiation of low-dose aspirin: a Danish population-based cohort study
por: Troelsen, Frederikke Schønfeldt, et al.
Publicado: (2020)

Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD
por: Pelaia, Girolamo, et al.
Publicado: (2015)

Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone
por: Tamura, Tomohiro, et al.
Publicado: (2016)

Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies
por: Singh, Dave, et al.
Publicado: (2016)

Hepatitis C virus infection and risk of cancer: a population-based cohort study
por: Omland, Lars Haukali, et al.
Publicado: (2010)

Validity of a procedure to identify patients with chronic idiopathic thrombocytopenic purpura in the Danish National Registry of Patients
por: Heden, Katrine Edith Klith, et al.
Publicado: (2009)

One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2–4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis
por: McGarvey, Lorcan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1htbg9js2ijj16347g3lcvgf22